Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,722 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Administration first Clear all
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

NCT03592277
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Vitamin C, Vitamin B1
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

NCT02728752
View directory record Official record
Conditions
Dermatomyositis
Interventions
Octagam 10%, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Huntington Beach, California • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 9, 2026, 9:57 PM EDT
Withdrawn Phase 2 Interventional

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

NCT05216614
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Parosmia
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Not applicable Interventional

Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

NCT06146504
View directory record Official record
Conditions
Candida Systemic, Candida Albicans Infection, Candida Infection
Interventions
CanXida Remove (Formula RMV), Placebo
Dietary Supplement · Other
Lead sponsor
CanXida
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Not applicable Interventional Results available

Safe Administration of Flu Vaccine to Egg Allergic Children

NCT01264601
View directory record Official record
Conditions
Egg Allergy
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01418222
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-FU, FOLFOX regimen, Placebo, bevacizumab [Avastin], leucovorin, onartuzumab [MetMAb]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Fort Myers, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 9, 2026, 9:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

NCT04520139
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

NCT02594254
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Gel, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

NCT03255629
View directory record Official record
Conditions
Post-bariatric Hypoglycemia
Interventions
glucagon, Closed loop glucagon pump
Drug · Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Short Term Effects of Oceanix Supplementation on Recovery

NCT04315077
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Muscle Damage, Immune Suppression
Interventions
Oceanix®, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 9, 2026, 9:57 PM EDT
Recruiting Early Phase 1 Interventional

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

NCT05921253
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
PARASYM neuromodulation device
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Not applicable Interventional Results available

Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

NCT01832753
View directory record Official record
Conditions
Down Syndrome, Subclinical Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 20 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 9, 2026, 9:57 PM EDT
Recruiting Phase 4 Interventional

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

NCT06569212
View directory record Official record
Conditions
Non-Traumatic Subarachnoid Hemorrhage
Interventions
Metoprolol, Placebo
Drug
Lead sponsor
Madeleine Puissant
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional

Memory Improvement Through Nicotine Dosing (MIND) Study

NCT02720445
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Nicotine Transdermal Patch, Placebo Patch
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
36
States / cities
Scottsdale, Arizona • North Little Rock, Arkansas • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 9, 2026, 9:57 PM EDT
Not listed Phase 3 Interventional

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

NCT04033354
View directory record Official record
Conditions
Squamous Non Small Cell Lung Cancer
Interventions
HLX10, carboplatin and nab paclitaxel, Placebo
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 1 Interventional

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

NCT01803867
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
rHIgM22
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Long Beach, California • Palo Alto, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional

Investigation of Sleep in the Intensive Care Unit

NCT03355053
View directory record Official record
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 9, 2026, 9:57 PM EDT
Completed Phase 2 Interventional

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

NCT05948592
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
TP-102, Placebo
Biological · Other
Lead sponsor
Technophage, SA
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 9, 2026, 9:57 PM EDT